BB-1712
/ BlissBio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 26, 2025
Preclinical studies of BB-1712: A B7H3-targeting eribulin-containing ADC with the potential to overcome resistance to DNA topoisomerase I inhibitor-containing ADCs
(AACR 2025)
- "In this study, we introduce BB-1712, a novel B7-H3-targeting ADC that incorporates eribulin as its cytotoxic payload, with the potential to treat patients not sensitive to ADCs containing DNA topoisomerase I inhibitors as payload toxin such as DS-7300a. Pharmacokinetic and toxicology assessments in non-human primates revealed a favorable safety profile for BB-1712 at clinically relevant dosages and administration schedules.In summary, our findings suggest that BB-1712 has promising preclinical efficacy and safety profiles as well as the potential to circumvent resistance mechanisms associated with current therapies. These results support the advancement of BB-1712 into clinical trials for patients with B7-H3-expressing solid tumors."
Preclinical • Breast Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • CD276
November 16, 2024
The IND application of Bioscan's innovative ADC drug BB-1712 was approved by the China National Medical Products Administration [Google translation]
(pharnexcloud.com)
- "On November 14, 2024, China time, BlissBio's innovative tumor-targeted antibody-drug conjugate (ADC) BB-1712 Phase I clinical trial application (IND) was approved by the China National Medical Products Administration (NMPA) (acceptance number: CXSL2400589). BB-1712 is an innovative ADC targeting B7-H3 and using eribulin as a toxin, and is intended to be developed for the treatment of a variety of solid tumors."
New P1 trial • Oncology • Solid Tumor
October 17, 2024
The IND application of Bioscan’s innovative ADC drug BB-1712 was approved by the US FDA [Google translation]
(vbdata.cn)
- "Bioscan's innovative ADC drug BB-1712 has been approved by the U.S. FDA for its Phase I clinical trial application. It is intended to be used to treat a variety of solid tumors. The company looks forward to its subsequent clinical research performance."
IND • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1